| Current status of drug-eluting stents |
|
Sung-Hwan Kim, Myeong-Ki Hong |
|
성균관 의과 대학교 삼성 서울 병원 심혈관 센터 순환기 내과 |
| 특집: 약물방출 스텐트의 최근 동향 |
|
김성환.홍명기, Myeong-Ki Hong |
|
|
|
|
|
|
| Abstract |
|
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
The percutaneous coronary intervention (PCI) has been a great advance in the treatment of coronary artery disease
since implantation of bare metal stents (BMS) decreased acute recoil and arterial shrinkage caused by balloon angioplasty.
However, neointimal hyperplasia leading to in-stent restenosis after BMS implantation has been emerged a new obstacle.
Recent introduction of drug-eluting stents (DES) contributes a powerful breakthrough to PCI. Many large well-controlled
randomized trials have shown that DES remarkably reduces restenosis and target vessel revascularization in de novo
lesions when compared with BMS. Therefore the application of DES have been expanded to the complex lesions such as
left main, multi-vessel, bifurcation, in-stent restenosis, or chronic total occlusion. The safety and effectiveness of DES are
still under evaluation with ongoing trials. However, some problems such as very late stent thrombosis remained to be
solved. In this review article, we summarize the past, present and future of DES with updated result of clinical trials.
(Korean J Med 75:370-382, 2008) |
| Key Words:
Drug-eluting stents; Percutaneous transluminal coronary angioplasty |
|
PDF Links
Full text via DOI
Download Citation
